Lack of benefit from nitric oxide synthase inhibition in patients with cardiogenic shock: looking for the reasons.
Ndrepepa
Gjin
G
Schömig
Albert
A
Kastrati
Adnan
A
D001120:Arginine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors*; D012770:Shock, Cardiogenic / Q000188:drug therapy*; D014662:Vasoconstrictor Agents / Q000627:therapeutic use*; D019323:omega-N-Methylarginine
D001120:Arginine; D004791:Enzyme Inhibitors; D019001:Nitric Oxide Synthase; D014662:Vasoconstrictor Agents; C092506:N(G)-monomethylarginine acetate; D019323:omega-N-Methylarginine